痰热清治疗对AECOPD患者症状、血气、肺功能指标及炎性因子水平的影响  

Effects of Phlegmyheatclear Treatment on the Symptoms, Blood gas, Lung Function and serum Inflammatory Factors Levels of AECOPD Patients

作　　者：俞洋[1] 欧阳洋[1] 杨晓龙[1] 张学人 朱辉 YU Yang;OUYANG Yang;YANG Xiao-long;ZHANG Xue-ren;ZHU Hui(Emergency Department,the Affiliated Hospital of Shanghai University of Traditional Chinese Medicine,Shanghai,201203,China)

机构地区：[1]上海中医药大学附属曙光医院急诊内科,上海201203

出　　处：《现代生物医学进展》2020年第5期897-900,共4页Progress in Modern Biomedicine

基　　金：上海曙光医院"四明"基金项目(SGKI-201720)。

摘　　要：目的:探究痰热清对慢性阻塞性肺疾病发作加重期(AECOPD)患者的症状、血气、肺功能指标及炎症反应的影响。方法:选择2017年10月至2018年10月在本院就诊的AECOPD患者共100例,将其随机分为A组(对照组)和B组(研究组),每组各50例。A组进行常规治疗,B组在A组治疗方案的基础上给予痰热清治疗,比较两组患者的治疗效果、治疗前后血气指标、肺功能及血清炎症因子水平的变化。结果:治疗后,B组咳嗽、呼吸困难和啰音消失时间显著性短于A组(P<0.05);两组血氧饱和度(SpO2)均较治疗前显著上升(P<0.05),动脉血二氧化碳分压(PaCO2)、血清白细胞介素-1(IL-1)、C反应蛋白(CRP)和降钙素(PCT)水平均较治疗前显著降低(P<0.05),且B组SpO2显著高于A组(P<0.05),PaCO2及血清IL-1、CRP及PCT水平均显著低于A组(P<0.05)。结论:痰热清辅助常规治疗可显著改善AECOPD患者临床症状,有效改善肺功能,减轻炎症反应。Objective: To explore the effect of phlegmyheatclear on the symptoms, blood gas, lung function and inflammatory response in patients with exacerbation of chronic obstructive pulmonary disease(AECOPD). Methods: 100 patients with AECOPD who were treated in our hospital from October 2017 to October 2018 were selected and randomly divided into group A(control group) and group B(study group), with 50 cases in each group. Group A was treated with conventional therapy, while group B was treated with phlegmyheatclear on the basis of treatment plan of group A, the therapeutic effect, changes of blood gas index, lung function and serum inflammatory factors before and after treatment were compared between two groups. Results: After treatment, the coughing, dyspnea and rale disappearance time of group B were significantly shorter than those of group A(P<0.05). The blood oxygen saturation of both groups(SpO2) were significantly increased after treatment(P<0.05), and the levels of arterial carbon dioxide partial pressure(PaCO2), serum interleukin-1(il-1), c-reactive protein(CRP) and calcitonin(PCT) were significantly decreased(P<0.05), the SpO2 levels in group B were significantly higher than those of group A(P<0.05), and the levels of PaCO2 and serum IL-1, CRP and PCT were significantly lower than those of group A(P<0.05). Conclusion: Phlegmyheatclear can significantly improve the clinical symptoms of AECOPD patients, it can effectively improve the lung function, reduce the inflammatory response.

关 键 词：痰清热 慢性阻塞性肺疾病发作加重期 肺功能 炎症因子 

分 类 号：R563[医药卫生—呼吸系统]